The 121 Amino Acid Isoform of Vascular Endothelial Growth Factor is More Strongly Tumorigenic Than Other Splice Variants in Vivo

Overview

Journal Br J Cancer

Specialty Oncology

Date 2000 Jul 7

PMID 10883669

Citations 51

Authors

H T Zhang

P A Scott

L Morbidelli

S Peak

J Moore

H Turley

A L Harris

M Ziche

R Bicknell

Affiliations

Soon will be listed here.

Abstract

Vascular endothelial growth factor (VEGF) is known to occur as at least six differentially spliced variants, giving rise to mature isoforms containing 121, 145, 165, 183, 189 and 206 amino acids. However, little is yet known concerning the in vivo activities of this differential splicing. Stably transfected MCF-7 breast carcinoma cells were constructed that secreted comparable amounts of the 121, 165 or 189 isoforms. Rabbit corneal angiogenesis assays showed the VEGF121 transfectant to have much greater angiogenic activity than the 165 or 189 expressing MCF-7 cells. While the VEGF121-expressing MCF-7 cells were reproducibly more tumorigenic than the control transfectants, this was not the case with the VEGF165- or VEGF189-expressing cells. More surprising was the observation that VEGF189 located to the nucleus, consistent with the presence of a highly conserved nuclear localization sequence in exon 6a that is expressed in VEGF189 but not 121 or 165. It was concluded that the VEGF121 isoform is both more angiogenic and tumorigenic than are the 165 and 189 isoforms. This is probably due to the ability of the 121 isoform, unlike the 165 and 189 isoforms, to freely diffuse from the cells producing it.

Citing Articles

Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective.

Jt S, M H, Wam B, Ac B, Sa N J Mol Med (Berl). 2022; 100(6):875-901.

PMID: 35606652 PMC: 9126699. DOI: 10.1007/s00109-022-02208-0.

How VEGF-A and its splice variants affect breast cancer development - clinical implications.

Al Kawas H, Saaid I, Jank P, Westhoff C, Denkert C, Pross T Cell Oncol (Dordr). 2022; 45(2):227-239.

PMID: 35303290 PMC: 9050780. DOI: 10.1007/s13402-022-00665-w.

Anti-Angiogenic Treatments Interact with Steroid Secretion in Inflammatory Breast Cancer Triple Negative Cell Lines.

Alonso-Diez A, Caceres S, Pena L, Crespo B, Illera J Cancers (Basel). 2021; 13(15).

PMID: 34359570 PMC: 8345132. DOI: 10.3390/cancers13153668.

VEGFA's distal enhancer regulates its alternative splicing in CML.

Dahan S, Sharma A, Cohen K, Baker M, Taqatqa N, Bentata M NAR Cancer. 2021; 3(3):zcab029.

PMID: 34316716 PMC: 8276762. DOI: 10.1093/narcan/zcab029.

Exploring the Intracrine Functions of VEGF-A.

Wiszniak S, Schwarz Q Biomolecules. 2021; 11(1).

PMID: 33478167 PMC: 7835749. DOI: 10.3390/biom11010128.

References

Gimbrone Jr M, COTRAN R, Leapman S, Folkman J . Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst. 1974; 52(2):413-27. DOI: 10.1093/jnci/52.2.413. View

Carmeliet P, Ng Y, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I . Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med. 1999; 5(5):495-502. DOI: 10.1038/8379. View

Robbins J, Dilworth S, Laskey R, Dingwall C . Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence. Cell. 1991; 64(3):615-23. DOI: 10.1016/0092-8674(91)90245-t. View

Tischer E, Mitchell R, Hartman T, Silva M, GOSPODAROWICZ D, Fiddes J . The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991; 266(18):11947-54. View

Houck K, Ferrara N, Winer J, Cachianes G, Li B, Leung D . The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991; 5(12):1806-14. DOI: 10.1210/mend-5-12-1806. View

Houck K, Leung D, Rowland A, Winer J, Ferrara N . Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem. 1992; 267(36):26031-7. View

Smith K, Houlbrook S, Greenall M, Carmichael J, Harris A . Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene. 1993; 8(4):933-8. View

Park J, Keller G, Ferrara N . The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993; 4(12):1317-26. PMC: 275767. DOI: 10.1091/mbc.4.12.1317. View

Ziche M, Morbidelli L, Masini E, Amerini S, Granger H, Maggi C . Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest. 1994; 94(5):2036-44. PMC: 294636. DOI: 10.1172/JCI117557. View

10.

Bader T, Weitzerbin J . Nuclear accumulation of interferon gamma. Proc Natl Acad Sci U S A. 1994; 91(25):11831-5. PMC: 45329. DOI: 10.1073/pnas.91.25.11831. View

11.

Zhang H, Craft P, Scott P, Ziche M, Weich H, Harris A . Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst. 1995; 87(3):213-9. DOI: 10.1093/jnci/87.3.213. View

12.

Coltrini D, Gualandris A, Nelli E, Parolini S, Quarto N, Ziche M . Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Res. 1995; 55(20):4729-38. View

13.

Keyt B, Berleau L, Nguyen H, Chen H, HEINSOHN H, Vandlen R . The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996; 271(13):7788-95. DOI: 10.1074/jbc.271.13.7788. View

14.

Cohen T, Tessler S, Soker S, Gengrinovitch S, Rockwell P, Klagsbrun M . Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem. 1996; 271(10):5519-23. DOI: 10.1074/jbc.271.10.5519. View

15.

Siemeister G, SCHNURR B, Mohrs K, Schachtele C, Marme D, Martiny-Baron G . Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli. Biochem Biophys Res Commun. 1996; 222(2):249-55. DOI: 10.1006/bbrc.1996.0730. View

16.

Relf M, Lejeune S, Scott P, Fox S, Smith K, Leek R . Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human.... Cancer Res. 1997; 57(5):963-9. View

17.

Ziche M, Morbidelli L, Choudhuri R, Zhang H, Donnini S, Granger H . Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997; 99(11):2625-34. PMC: 508108. DOI: 10.1172/JCI119451. View

18.

Grutzkau A, Kruger-Krasagakes S, Baumeister H, Schwarz C, KOGEL H, Welker P . Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell. 1998; 9(4):875-84. PMC: 25314. DOI: 10.1091/mbc.9.4.875. View

19.

Cheung N, Wong M, Yuen S, Leung S, Chung L . Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol. 1998; 29(9):910-4. DOI: 10.1016/s0046-8177(98)90195-2. View

20.

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z . Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13(1):9-22. View